iBB
46.4K views | +5 today
Follow
iBB
Institute for Bioengineering and Biosciences
Curated by iBB
Your new post is loading...
Your new post is loading...
Scoop.it!

Production of Extracellular Vesicles Derived from Mesenchymal Stromal Cells in Bioreactors

Production of Extracellular Vesicles Derived from Mesenchymal Stromal Cells in Bioreactors | iBB | Scoop.it

Cell-based therapies have been showing unprecedented therapeutic potential, already changing the landscape of medical care. Extracellular vesicles are nanoparticles naturally secreted by cells, which are important mediators of intercellular communication in our organism and are able to mediate therapeutic effects from their cells of origin. These vesicles can also be used as drug delivery vehicles to target multiple diseases. In a paper recently published in Frontiers in Cell and Developmental Biology, iBB researchers in collaboration with iMM Lisboa, CQE-IST and the companies PBS Biotech and AventaCell Biomedical, developed a new strategy for the robust and scalable production of extracellular vesicles from mesenchymal stromal cells, using bioreactors and an animal serum-free cell culture supplement. This strategy, developed within the frame of the PhD Program in Bioengineering of Miguel de Almeida Fuzeta, is a relevant step towards the large scale production of extracellular vesicles form different human tissue sources, which are promising tools for the development of new therapies against a variety of diseases, from cardiovascular diseases to cancer.

No comment yet.
Scoop.it!

Manufacturing of Therapeutic Exosomes

Manufacturing of Therapeutic Exosomes | iBB | Scoop.it

The project "EXOpro: Development of a scalable manufacturing process for therapeutic human mesenchymal stem/stromal cell-derived exosomes" has been recommended for funding by FCT. The goal of EXOpro is to develop a fully controlled manufacturing process for the production and purification of an effective, safe and fully characterized MSC-derived exosome-based product. Overall, the success of this project is expected to contribute to the development of novel cell-free strategies for  Regenerative Medicine settings. The project, which falls within the scientific area of Chemical Engineering, is headed by Ana Fernandes from SCERG-iBB and Ana Azevedo from BERG-iBB and involves a collaboration with the University of São Paulo.

Photo details: GFP-expressing MSCs by Joana Serra, copyright iBB 2017.

No comment yet.
Scoop.it!

Tailored Cytokine Optimization for ex vivo Expansion of Human Hematopoietic Stem/Progenitor Cells

Tailored Cytokine Optimization for ex vivo Expansion of Human Hematopoietic Stem/Progenitor Cells | iBB | Scoop.it

Umbilical cord blood (UCB) is an accepted and appealing alternative source of hematopoietic stem/progenitor cells (HSPC) for hematopoietic cell transplants. However, low UCB volume recovered from births results in an unsatisfactory cell dose for transplants in adults, having initially limited transplants of a single UCB unit to pediatric patients. Ex vivo expansion of HSPC based on the addition of exogenous cytokines.has been pursued to address this problem. Notably, selection of individual cytokines and their concentrations for an expansion cocktail has differed between existing strategies. To improve the effectiveness of these platforms, namely targeting clinical approval, iBB researchers optimized the cytokine cocktails in two clinically relevant expansion platforms for HSPC, a liquid suspension culture system (CS_HSPC) and a co-culture system with bone marrow derived mesenchymal stromal cells (CS_HSPC/MSC).. The tailored and novel optimized cocktails determined made it possible to individually maximize cytokine contribution in both studied platforms, leading to an increase in the expansion platform performance, while allowing a rational side-by-side comparison between them and enhancing our knowledge on the impact of cytokine supplementation on the HSPC expansion process. The results achieved were published in Frontiers in Bioengineering and Biotechnology, Stem Cell Systems Bioengineering section.

No comment yet.